184 related articles for article (PubMed ID: 29391352)
1. PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer.
Lamprecht S; Kaller M; Schmidt EM; Blaj C; Schiergens TS; Engel J; Jung A; Hermeking H; Grünewald TGP; Kirchner T; Horst D
Clin Cancer Res; 2018 Apr; 24(8):1974-1986. PubMed ID: 29391352
[No Abstract] [Full Text] [Related]
2. PBX3 hypermethylation in peripheral blood leukocytes predicts better prognosis in colorectal cancer: A propensity score analysis.
Sun H; Huang H; Li D; Zhang L; Zhang Y; Xu J; Liu Y; Liu Y; Zhao Y
Cancer Med; 2019 Jul; 8(8):4001-4011. PubMed ID: 31140752
[TBL] [Abstract][Full Text] [Related]
3. PBX3 promotes migration and invasion of colorectal cancer cells via activation of MAPK/ERK signaling pathway.
Han HB; Gu J; Ji DB; Li ZW; Zhang Y; Zhao W; Wang LM; Zhang ZQ
World J Gastroenterol; 2014 Dec; 20(48):18260-70. PubMed ID: 25561793
[TBL] [Abstract][Full Text] [Related]
4. PBXIP1 - An indicator for poor outcome and metastatic spread in colorectal cancer.
Ilmer M; Renz BW; Kühn F; Drefs M; Koliogiannis D; Werner J; Kirchner T; Horst D; Woischke C
Pathol Res Pract; 2022 Aug; 236():153993. PubMed ID: 35785747
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3.
Li B; Zhang S; Shen H; Li C
Biochem Biophys Res Commun; 2017 Mar; 484(2):241-247. PubMed ID: 28111340
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
[TBL] [Abstract][Full Text] [Related]
7. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation.
Ono H; Imoto I; Kozaki K; Tsuda H; Matsui T; Kurasawa Y; Muramatsu T; Sugihara K; Inazawa J
Oncogene; 2012 Nov; 31(47):4923-34. PubMed ID: 22286765
[TBL] [Abstract][Full Text] [Related]
8. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
[TBL] [Abstract][Full Text] [Related]
9. Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Yang J; Zhang K; Song H; Wu M; Li J; Yong Z; Jiang S; Kuang X; Zhang T
Oncotarget; 2016 May; 7(22):32306-17. PubMed ID: 27058759
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer.
Kahlert C; Lerbs T; Pecqueux M; Herpel E; Hoffmeister M; Jansen L; Brenner H; Chang-Claude J; Bläker H; Kloor M; Roth W; Pilarsky C; Rahbari NN; Schölch S; Bork U; Reissfelder C; Weitz J; Aust D; Koch M
Int J Cancer; 2015 Nov; 137(9):2104-13. PubMed ID: 25951369
[TBL] [Abstract][Full Text] [Related]
11. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer.
Han HB; Gu J; Zuo HJ; Chen ZG; Zhao W; Li M; Ji DB; Lu YY; Zhang ZQ
J Pathol; 2012 Feb; 226(3):544-55. PubMed ID: 21984339
[TBL] [Abstract][Full Text] [Related]
12. miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFβ-mediated epithelial to mesenchymal transition.
Zhao S; Sun H; Jiang W; Mi Y; Zhang D; Wen Y; Cheng D; Tang H; Wu S; Yu Y; Liu X; Cui W; Zhang M; Sun X; Zhou Z; Peng Z; Yan D
Mol Cancer; 2017 Jan; 16(1):12. PubMed ID: 28095858
[TBL] [Abstract][Full Text] [Related]
13. CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
Woischke C; Blaj C; Schmidt EM; Lamprecht S; Engel J; Hermeking H; Kirchner T; Horst D
Oncotarget; 2016 May; 7(21):31350-60. PubMed ID: 27120783
[TBL] [Abstract][Full Text] [Related]
14. The role of microRNA-200 in progression of human colorectal and breast cancer.
Bojmar L; Karlsson E; Ellegård S; Olsson H; Björnsson B; Hallböök O; Larsson M; Stål O; Sandström P
PLoS One; 2013; 8(12):e84815. PubMed ID: 24376848
[TBL] [Abstract][Full Text] [Related]
15. MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
Su L; Luo Y; Yang Z; Yang J; Yao C; Cheng F; Shan J; Chen J; Li F; Liu L; Liu C; Xu Y; Jiang L; Guo D; Prieto J; Ávila MA; Shen J; Qian C
Cancer Res; 2016 Sep; 76(17):5054-67. PubMed ID: 27364559
[TBL] [Abstract][Full Text] [Related]
16. ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.
Liu D; Skomorovska Y; Song J; Bowler E; Harris R; Ravasz M; Bai S; Ayati M; Tamai K; Koyuturk M; Yuan X; Wang Z; Wang Y; Ewing RM
Cancer Biol Ther; 2019; 20(1):90-100. PubMed ID: 30148686
[No Abstract] [Full Text] [Related]
17. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer.
Zhang W; Shi X; Peng Y; Wu M; Zhang P; Xie R; Wu Y; Yan Q; Liu S; Wang J
PLoS One; 2015; 10(6):e0129603. PubMed ID: 26057751
[TBL] [Abstract][Full Text] [Related]
18. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1.
Zhang M; Miao F; Huang R; Liu W; Zhao Y; Jiao T; Lu Y; Wu F; Wang X; Wang H; Zhao H; Ju H; Miao S; Wang L; Song W
J Exp Clin Cancer Res; 2018 Feb; 37(1):22. PubMed ID: 29426364
[TBL] [Abstract][Full Text] [Related]
19. The integrated pathway of TGFβ/Snail with TNFα/NFκB may facilitate the tumor-stroma interaction in the EMT process and colorectal cancer prognosis.
Li H; Zhong A; Li S; Meng X; Wang X; Xu F; Lai M
Sci Rep; 2017 Jul; 7(1):4915. PubMed ID: 28687755
[TBL] [Abstract][Full Text] [Related]
20. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
